173 results on '"Friede, Martin"'
Search Results
2. Contributors
3. A Practical Guide to Full Value of Vaccine Assessments
4. Key considerations for the development of novel mRNA candidate vaccines in LMICs: A WHO/MPP mRNA Technology Transfer Programme meeting report
5. IABS/CEPI platform technology webinar: Is it possible to reduce the vaccine development time?
6. HIV immunoprophylaxis: preparing the pathway from proof of concept to policy decision and use
7. Tracking progress in universal influenza vaccine development
8. Bacillus Calmette-Guérin (BCG) vaccine: A global assessment of demand and supply balance
9. H7N9 influenza split vaccine with SWE oil-in-water adjuvant greatly enhances cross-reactive humoral immunity and protection against severe pneumonia in ferrets
10. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial
11. Experimental Therapies for Ebola Virus Disease: What Have We Learned?
12. Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications
13. Accelerating the development of vaccine microarray patches for epidemic response and equitable immunization coverage requires investment in microarray patch manufacturing facilities
14. Accelerating access for all through research and innovation in immunization: Recommendations from Strategic Priority 7 of the Immunization Agenda 2030
15. Contributors
16. Evolution of Adjuvants Across the Centuries
17. Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trial
18. Technology transfer programme for influenza vaccines – Lessons from the past to inform the future
19. Chapter 7 - Evolution of Adjuvants Across the Centuries
20. Leveraging mRNA Platform Technology to Accelerate Development of Vaccines for Some Emerging and Neglected Tropical Diseases Through Local Vaccine Production
21. Synthetic and Natural TLR4 Agonists as Safe and Effective Vaccine Adjuvants
22. Randomized Controlled Clinical Trial of Fractional Doses of Inactivated Poliovirus Vaccine Administered Intradermally by Needle-Free Device in Cuba
23. A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future
24. Seasonal influenza vaccination policies in the 194 WHO Member States: The evolution of global influenza pandemic preparedness and the challenge of sustaining equitable vaccine access
25. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations
26. Evolving pharmacovigilance requirements with novel vaccines and vaccine components
27. New horizons in adjuvants for vaccine development
28. Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits
29. Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: A World Health Organization Action Framework
30. Evolution of adjuvants across the centuries
31. List of Contributors
32. Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans
33. A review of human vaccine research and development: Malaria
34. A new tuberculosis vaccine: breakthrough, challenges, and a call for collaboration
35. Meeting report: Global vaccine and immunization research forum, 2018
36. Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics
37. Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics
38. Quadrivalent influenza vaccines in low and middle income countries: Cost-effectiveness, affordability and availability
39. Report on WHO meeting on immunization in older adults: Geneva, Switzerland, 22–23 March 2017
40. 6 - Evolution of Adjuvants Across the Centuries
41. A cost analysis of producing vaccines in developing countries
42. WHO/IVI global stakeholder consultation on group A Streptococcus vaccine development: Report from a meeting held on 12–13 December 2016
43. Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation
44. Therapeutic antibodies for infectious diseases
45. Developing a vaccine against Zika
46. Author’s reply: Regarding the editorial by Penttinen and Friede
47. Decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines: an observational bias or a technical challenge?
48. 5 - Evolution of adjuvants across the centuries
49. Understanding history, philanthropy and the role of WHO in provision of assistive technologies for hearing loss
50. Study of safety and immunogenicity of Measles vaccine (Rouvax®) administered by transcutaneous route (France)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.